Rapid Nutrition (ALRPD) investor relations material

Executive summary

• FY2025 was a deliberate transition year, focusing on repositioning from a supplement business to a global AI-enabled HealthTech platform, with significant investment in digital infrastructure and personalisation capabilities.

• A €5.0 million cornerstone equity investment was secured, materially strengthening the balance sheet and liquidity.

• Legacy short-term financing arrangements were resolved, simplifying the capital structure and reducing future financial complexity.

• Revenue was intentionally moderated during operational restructuring, with management prioritising long-term scalability over short-term growth.

• By year-end, the group had completed most strategic initiatives, improving readiness for international expansion.

Financial highlights

• Revenue for FY2025 was $194,326, down from $917,044 in FY2024, reflecting intentional moderation during restructuring.

• Gross profit was $52,929 (FY2024: $482,092); operating loss was $3,101,665 (FY2024: $3,009,567).

• Cash and cash equivalents increased to $8,550,850 (FY2024: $95,809) due to the equity investment.

• Trade and other receivables decreased to $82,769 (FY2024: $425,941), reflecting conservative commercial activity.

• No dividends were paid or proposed; all profits retained for growth.

Outlook and guidance

• Management expects improved revenue conversion and commercial execution in FY2026, with early indicators showing better trading performance.

• Focus will increase on direct-to-consumer channels in key markets (UK, Europe, Australia, China, US) over the next 12 months.

• The group is positioned to convert growing global demand into revenue growth, supported by a strengthened balance sheet.